LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates in two segments, Cardiovascular (CV) and Neuromodulation (NM). The CV segment develops, produces, and sells cardiopulmonary products, including heart-lung machines, oxygenators, perfusion tubing sets, cannulae, and accessories, as well as related equipment and disposables for autotransfusion and autologous blood washing for neonatal, pediatric, and adult patients.
Read More…
Industry, Sector and Symbol
Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
Phone44-0-20-3325-0660
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.11 billion
Profitability
Miscellaneous
Employees4,000
Next Earnings Date2/26/2020 (Confirmed)
OptionableOptionable
LivaNova (NASDAQ:LIVN) Frequently Asked Questions
What is LivaNova's stock symbol?
LivaNova trades on the NASDAQ under the ticker symbol "LIVN."
How were LivaNova's earnings last quarter?
LivaNova PLC (NASDAQ:LIVN) posted its earnings results on Wednesday, October, 30th. The company reported $0.84 EPS for the quarter, beating the Zacks' consensus estimate of $0.75 by $0.09. The company had revenue of $268.60 million for the quarter, compared to the consensus estimate of $273.41 million. LivaNova had a positive return on equity of 9.44% and a negative net margin of 20.35%. The company's revenue for the quarter was down 1.3% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.78 earnings per share. View LivaNova's Earnings History.
When is LivaNova's next earnings date?
How can I listen to LivaNova's earnings call?
LivaNova will be holding an earnings conference call on Wednesday, February 26th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.
What price target have analysts set for LIVN?
6 brokerages have issued 1-year price objectives for LivaNova's shares. Their forecasts range from $88.00 to $114.00. On average, they anticipate LivaNova's share price to reach $97.40 in the next year. This suggests a possible upside of 38.4% from the stock's current price. View Analyst Price Targets for LivaNova.
What is the consensus analysts' recommendation for LivaNova?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for LivaNova in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for LivaNova.
What are Wall Street analysts saying about LivaNova stock?
Here are some recent quotes from research analysts about LivaNova stock:
- 1. According to Zacks Investment Research, "LivaNova PLC is a medical technology company which focuses on providing treatment for cardiovascular diseases and neuromodulation. The Company's operating units consists of Cardiac Rhythm Management, Cardiac Surgery and Neuromodulation. LivaNova PLC, formerly known as Cyberonics, Inc., is based in London, United Kingdom. " (2/6/2020)
- 2. BTIG Research analysts commented, "As expected, LIVN revised down FY19 guidance following the pre- announcement. Although we had taken down estimates following the miss, the cut to the U.S. Neuromod outlook was still $10-20M worse than we expected. FY19 EPS is now expected to reach $3.00-3.10, ~$0.15 lower than our already lowered $3.21 forecast. Comps turn more difficult on the base business but with a fuller impact from Epidiolex going forward and no imminent relief in the lagging Heart valves business, we feel that even meeting the low end of the 1-3% constant currency guidance could prove challenging. Optics should improve in the back half when the TRD trial begins to enroll but even successful enrollment and reimbursement are not entirely certain. Overall, we think it will take a few quarters to regain credibility and enhance investor confidence in a turnaround in FY20." (5/2/2019)
Has LivaNova been receiving favorable news coverage?
Media coverage about LIVN stock has been trending negative on Friday, according to InfoTrie. The research firm identifies negative and positive press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. LivaNova earned a daily sentiment score of -2.2 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for LivaNova.
Who are some of LivaNova's key competitors?
Some companies that are related to LivaNova include Varian Medical Systems (VAR), Masimo (MASI), GETINGE AB/ADR (GNGBY), CONMED (CNMD), InMode (INMD), Natus Medical (NTUS), AxoGen (AXGN), TransMedics Group (TMDX), Cutera (CUTR), Zynex (ZYXI), Semler Scientific (SMLR), BioLife Solutions (BLFS), Viewray (VRAY), Stereotaxis (STXS) and Rockwell Medical (RMTI).
What other stocks do shareholders of LivaNova own?
Who are LivaNova's key executives?
LivaNova's management team includes the folowing people:
- Mr. Damien McDonald, CEO & Director (Age 54)
- Mr. Thad Huston, Chief Financial Officer (Age 49)
- Mr. Douglas J. Manko, Chief Accounting Officer (Age 45)
- Ms. Keyna Pidcock Skeffington, Gen. Counsel & Sr. VP (Age 56)
- Mr. David S. Wise, Sr. Advisor (Age 64)
Who are LivaNova's major shareholders?
LivaNova's stock is owned by a number of of institutional and retail investors. Top institutional investors include Franklin Resources Inc. (6.92%), Capital Research Global Investors (4.56%), UBS Asset Management Americas Inc. (3.62%), State Street Corp (3.27%), Pictet Asset Management Ltd. (2.42%) and Geode Capital Management LLC (1.39%). Company insiders that own LivaNova stock include Alfred J Novak, Alistair Simpson, Damien Mcdonald, Daniel Jeffrey Moore, David S Wise, Douglas John Manko, Francesco Bianchi, Hugh M Morrison, Thad Allen Huston and William A Kozy. View Institutional Ownership Trends for LivaNova.
Which major investors are selling LivaNova stock?
LIVN stock was sold by a variety of institutional investors in the last quarter, including Capital Research Global Investors, Lord Abbett & CO. LLC, Penn Capital Management Co. Inc., Goldman Sachs Group Inc., New York State Common Retirement Fund, NWQ Investment Management Company LLC, Panagora Asset Management Inc. and Rothschild & Co. Asset Management US Inc.. Company insiders that have sold LivaNova company stock in the last year include Alfred J Novak, Damien Mcdonald, Daniel Jeffrey Moore and Thad Allen Huston. View Insider Buying and Selling for LivaNova.
Which major investors are buying LivaNova stock?
LIVN stock was acquired by a variety of institutional investors in the last quarter, including Pictet Asset Management Ltd., Bridger Management LLC, Capital International Investors, Paradice Investment Management LLC, Jacobs Levy Equity Management Inc., Franklin Resources Inc., Retirement Systems of Alabama and Rhenman & Partners Asset Management AB. View Insider Buying and Selling for LivaNova.
How do I buy shares of LivaNova?
Shares of LIVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is LivaNova's stock price today?
One share of LIVN stock can currently be purchased for approximately $70.39.
How big of a company is LivaNova?
LivaNova has a market capitalization of $3.41 billion and generates $1.11 billion in revenue each year. The company earns $-189,400,000.00 in net income (profit) each year or $3.17 on an earnings per share basis. LivaNova employs 4,000 workers across the globe.View Additional Information About LivaNova.
What is LivaNova's official website?
How can I contact LivaNova?
LivaNova's mailing address is 20 EASTBOURNE TERRACE, LONDON X0, W2 6LG. The company can be reached via phone at 44-0-20-3325-0660 or via email at [email protected]
MarketBeat Community Rating for LivaNova (NASDAQ LIVN)
MarketBeat's community ratings are surveys of what our community members think about LivaNova and other stocks. Vote "Outperform" if you believe LIVN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LIVN will underperform the S&P 500 over the long term. You may vote once every thirty days.
